Johnson & Johnson’s stock dropped more than 3% Wednesday after the medical-technology and drug company beat estimates for the fourth quarter but as lower sales guidance for the year stoked fears of ...

Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...

Johnson & Johnson, founded in 1886, makes and sells medical devices, pharmaceuticals, and consumer health products. Headquartered in New Brunswick, N.J., the company operates over 250 subsidiary ...

Johnson & Johnson expects full-year earnings in the range of $10.50 to $10.70 per share, with revenue in the range of $89.2 billion to $90 billion. This story was generated by Automated Insights ( ...

Her diagnosis was "a direct and proximate result of Ms Cartwright's inhalation and ingestion of asbestos contained within the J&J products," it alleged. Johnson & Johnson has denied the ...

Johnson & Johnson “should have known that the J&J Products contained harmful, deleterious, carcinogenic and inherently dangerous asbestos dust and fibers” and the products reportedly did not ...

In the latest trading session, Johnson & Johnson (JNJ) closed at $147.77, marking a +1.93% move from the previous day. The stock's performance was ahead of the S&P 500's daily loss of 0.21%. Elsewhere ...

Johnson & Johnson (JNJ ... Shares of this world's biggest maker of health care products have returned -6.2% over the past month versus the Zacks S&P 500 composite's +1.1% change.